[go: up one dir, main page]

ATE192189T1 - In vitro bildung von dentritischen zellen - Google Patents

In vitro bildung von dentritischen zellen

Info

Publication number
ATE192189T1
ATE192189T1 AT93908477T AT93908477T ATE192189T1 AT E192189 T1 ATE192189 T1 AT E192189T1 AT 93908477 T AT93908477 T AT 93908477T AT 93908477 T AT93908477 T AT 93908477T AT E192189 T1 ATE192189 T1 AT E192189T1
Authority
AT
Austria
Prior art keywords
dendritic cells
adoptive immunotherapy
cells
vitro
dentritic cells
Prior art date
Application number
AT93908477T
Other languages
English (en)
Inventor
Jacques Banchereau
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE192189T1 publication Critical patent/ATE192189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT93908477T 1992-03-30 1993-03-29 In vitro bildung von dentritischen zellen ATE192189T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400879A EP0563485A1 (de) 1992-03-30 1992-03-30 In-vitro-Erzeugung von menschlichen dendritischen Zellen
PCT/US1993/002639 WO1993020186A1 (en) 1992-03-30 1993-03-29 In vitro generation of human dendritic cells and uses thereof

Publications (1)

Publication Number Publication Date
ATE192189T1 true ATE192189T1 (de) 2000-05-15

Family

ID=8211642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908477T ATE192189T1 (de) 1992-03-30 1993-03-29 In vitro bildung von dentritischen zellen

Country Status (14)

Country Link
EP (2) EP0563485A1 (de)
JP (1) JP3492361B2 (de)
KR (1) KR100223395B1 (de)
AT (1) ATE192189T1 (de)
AU (2) AU682466B2 (de)
CA (1) CA2133316C (de)
DE (1) DE69328481T2 (de)
DK (1) DK0633930T3 (de)
ES (1) ES2145047T3 (de)
GR (1) GR3033761T3 (de)
MX (1) MX9301753A (de)
NZ (1) NZ251585A (de)
PT (1) PT633930E (de)
WO (1) WO1993020186A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260971T1 (de) * 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
DE4337396A1 (de) * 1993-10-26 1995-04-27 Beiersdorf Ag Humane Zellinien mit Langerhans-Zell-Charakteristik
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US6121044A (en) * 1995-07-12 2000-09-19 Dendreon Corporation Potent antigen presenting cell composition
US7361330B2 (en) 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
WO1998014561A1 (en) 1996-10-04 1998-04-09 Becton Dickinson And Company Identification of a cd34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
NZ335864A (en) 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
EP1016413A1 (de) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Menschliches Wachstumshormon (HGH) zur Stimulierung der Mobilisierung pluripotenter Hämatopoietischer Stammzellen
JP2001061469A (ja) * 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2002331704A1 (en) 2001-08-22 2003-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
EP1809737B9 (de) 2004-10-07 2011-10-05 Argos Therapeutics, Inc. Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US7867977B2 (en) 2005-11-03 2011-01-11 The United States Of America As Represented By The Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
EP3115469B1 (de) 2007-11-19 2020-04-29 Celera Corporation Lungenkrebsmarker und verwendungen davon
NZ591133A (en) 2008-09-02 2012-08-31 Inst Nat Sante Rech Med Novel melanoma antigen peptide and uses thereof
EP2714730A1 (de) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues antigenpeptid und dessen verwendungen
AU2012380679A1 (en) 2012-05-22 2014-10-30 Centre National De La Recherche Scientifique (Cnrs) Novel melanoma antigen peptide and uses thereof
US9475841B2 (en) 2012-05-22 2016-10-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Melanoma antigen peptide and uses thereof
EP3126374B1 (de) 2014-04-01 2018-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Isoliertes, donor-mhc-abgeleitetes peptid und verwendungen davon
JP2017515795A (ja) 2014-04-01 2017-06-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 単離されたドナーｍｈｃ由来ペプチド及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002531A1 (en) * 1989-08-17 1991-03-07 Peter Maccallum Cancer Institute Method for the modulation of haemopoiesis in a mammal
US5128259A (en) * 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor

Also Published As

Publication number Publication date
KR100223395B1 (ko) 1999-10-15
JP3492361B2 (ja) 2004-02-03
NZ251585A (en) 1997-07-27
PT633930E (pt) 2000-09-29
GR3033761T3 (en) 2000-10-31
CA2133316A1 (en) 1993-10-14
KR950700989A (ko) 1995-02-20
ES2145047T3 (es) 2000-07-01
AU3928993A (en) 1993-11-08
DE69328481T2 (de) 2000-09-07
DE69328481D1 (de) 2000-05-31
MX9301753A (es) 1993-09-01
EP0633930A1 (de) 1995-01-18
EP0563485A1 (de) 1993-10-06
DK0633930T3 (da) 2000-09-18
AU682466B2 (en) 1997-10-09
JPH07505527A (ja) 1995-06-22
CA2133316C (en) 2005-05-24
AU3155897A (en) 1997-11-20
EP0633930B1 (de) 2000-04-26
WO1993020186A1 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
ATE192189T1 (de) In vitro bildung von dentritischen zellen
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
DE69233435D1 (de) Vorläufer von für tumorabstossung verantwortlichen antigenen, die antigene und deren verwendungen
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
DK66692A (da) En mammal cytokin, il-11
EA200100509A1 (ru) Модифицированные экзосомы и их применение
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
NO880705D0 (no) Fremgangsmaate til fremstilling av makromolekylare platinaforbindelser med virkning mot kreft.
ATE184488T1 (de) Pharmazeutische zusammensetzungen, die ein anticytokin enthalten
ATE165010T1 (de) Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen
DE69032816D1 (de) Verwendung von oncostatin m zur suppression von mhc antigenen
CA2118309A1 (en) Lymphocyte Activation Antigen HB15, a Member of the Immunoglobulin Superfamily
DE69734974D1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
HUT61202A (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
ATE2442T1 (de) Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung.
ATE237338T1 (de) Allogene parakrine cytokine tumor impfstoffe
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
RU94040167A (ru) Соединения на основе реакции амадори, их применение, способ получения и составы на их основе
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
DE69022121D1 (de) Verfahren zur Herstellung eines Metastaseninhibitorenfaktors.
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee